Data Indicate OBM’s OBM1701 Diffuses into the Retina and RPE and Effectively Alleviates Choroidal Neovascularisation in wet-AMD Animal Model after Topically Applied Has Been Published on An Association for Research in Vision and Ophthalmology (ARVO) Official Journal – 19th August 2025

Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM1701, its leading drug candidate for the treatment of wet-AMD, has been published on the latest issue of the Translational Vision Science & Technology (TVST) journal, released on 19 August 2025.  TVST is an official prominent peer-reviewed journal published by the Association for Research in Vision and Ophthalmology (ARVO), an international community of eye and vision scientists and ophthalmologists.

The title of article is “OBM1701 Alleviates Choroidal Neovascularization in Experimental Animals Via Suppressing the Expression of HIF-1α in Retinal Pigment Epithelial Cells”. Article can be found from the website of https://pmc.ncbi.nlm.nih.gov/articles/PMC12369909/.

Results not only demonstrate the mechanism of actions (MOA) of how OBM1701 works but also shows topically applied OBM1701 can effectively diffuse into and residue in the retina without the need being injected into vitreous cavity of the eye. All of the current approved anti-wet-AMD drugs require to be repeatedly administrated by intravitreal injection that can cause some side effects, such as temporary discomfort, redness, and increased floaters in the vision.

The superior advantages of possible route of administration by giving with eye drops of OBM1701 over the current drugs strongly further indicates its tremendously high commercial value of developing OBM1701 into a novel therapeutic for wet-AMD patients and provide better care to the patients.